Alzheimer's disease drug trials show hints of efficacy

10/8/2012 | Forbes · HealthDay News

Eli Lilly & Co.'s experimental Alzheimer's disease drug solanezumab failed to meet trial objectives, but the drug did slow cognitive decline in patients with the mildest symptoms. Lilly will have to conduct a large-scale trial in patients at the earliest disease stages to obtain FDA approval, Matthew Herper writes. "And the potential for failure is still very very real," he notes.

View Full Article in:

Forbes · HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC